{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:52:51Z","timestamp":1789271571928,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.phrs.2013.05.005","type":"journal-article","created":{"date-parts":[[2013,6,2]],"date-time":"2013-06-02T13:04:44Z","timestamp":1370178284000},"page":"78-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data"],"prefix":"10.1016","volume":"74","author":[{"given":"Sara","family":"M\u00ednguez-M\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Sol\u00eds-Garc\u00eda del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Jord\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2013.05.005_bib0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov Disord"},{"issue":"Suppl. (1)","key":"10.1016\/j.phrs.2013.05.005_bib0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","article-title":"Epidemiology and etiology of Parkinson's disease: a review of the evidence","volume":"26","author":"Wirdefeldt","year":"2011","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0015","first-page":"196","article-title":"Activities of enzymes involved in the formation and destruction of biogenic amines in various areas of human brain","volume":"165","author":"Vogel","year":"1969","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.05.005_bib0020","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/BF00970600","article-title":"Inhibition of mao-b by (\u2212)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain","volume":"20","author":"Paterson","year":"1995","journal-title":"Neurochem Res"},{"key":"10.1016\/j.phrs.2013.05.005_bib0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00023210-200721080-00005","article-title":"Medical management of levodopa-associated motor complications in patients with Parkinson's disease","volume":"21","author":"Jankovic","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2013.05.005_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/NDT.S5190","article-title":"Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa\/levodopa\/entacapone (stalevo)","volume":"6","author":"Solla","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.phrs.2013.05.005_bib0035","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.amjopharm.2010.08.001","article-title":"Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence","volume":"8","author":"Tarrants","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.phrs.2013.05.005_bib0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP48633","article-title":"Medical treatment of Parkinson's disease: today and the future","volume":"48","author":"Gardian","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2013.05.005_bib0045","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [n-propargyl-1r(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase b","volume":"132","author":"Youdim","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phrs.2013.05.005_bib0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the presto study","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0060","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the tempo study","volume":"59","author":"Parkinson Study Group","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0065","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline mesylate, a new mao-b inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1517\/14740338.2013.790956","article-title":"Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease","author":"Sol\u00eds-Garc\u00eda del Pozo","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.phrs.2013.05.005_bib0075","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","article-title":"Monoamine oxidase type b inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients","volume":"329","author":"Ives","year":"2004","journal-title":"Br Med J"},{"key":"10.1016\/j.phrs.2013.05.005_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.baga.2012.05.006","article-title":"Indirect meta-analysis of randomized placebo-controlled clinical trials on rasagilina and selegiline in the symptomatic treatment of Parkinson's disease","volume":"2","author":"Jost","year":"2012","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.phrs.2013.05.005_bib0085","series-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.phrs.2013.05.005_bib0090","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (largo, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2013.05.005_bib0095","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","article-title":"A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the adagio study): rationale, design, and baseline characteristics","volume":"23","author":"Olanow","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0100","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/mds.23738","article-title":"The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study","volume":"26","author":"Hanagasi","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e31823b1da8","article-title":"Combined beneficial effect of rasagiline on motor function and depression in de novo pd","volume":"35","author":"Korchounov","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0110","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20145","article-title":"Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients","volume":"19","author":"Stern","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/NRL.0b013e31822f6872","article-title":"Rasagiline time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment","volume":"17","author":"Wilson","year":"2011","journal-title":"Neurologist"},{"key":"10.1016\/j.phrs.2013.05.005_bib0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/03007995.2012.752351","article-title":"Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease","volume":"29","author":"Viallet","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.phrs.2013.05.005_bib0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00702-012-0927-3","article-title":"Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease","volume":"120","author":"Muller","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.phrs.2013.05.005_bib0130","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1440-1819.2012.02339.x","article-title":"Hyposmia in Parkinson's disease","volume":"66","author":"Alvarez","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.phrs.2013.05.005_bib0135","first-page":"1","article-title":"Efficacy and safety of rasagiline as an adjunct to levodopa treatment in chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial","author":"Zhang","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease","volume":"61","author":"Parkinson Study Group","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/mds.20764","article-title":"Rasagiline improves quality of life in patients with early Parkinson's disease","volume":"21","author":"Biglan","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0150","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/mds.22402","article-title":"Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease","volume":"24","author":"Hauser","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0155","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/00207451003778744","article-title":"Long-term efficacy of rasagiline in early Parkinson's disease","volume":"120","author":"Lew","year":"2010","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.phrs.2013.05.005_bib0160","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/HYPERTENSIONAHA.108.115873","article-title":"Transtelephonic home blood pressure to assess the monoamine oxidase-b inhibitor rasagiline in Parkinson disease","volume":"52","author":"White","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2013.05.005_bib0165","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/01.wnl.0000210692.95595.1c","article-title":"Safety of rasagiline in elderly patients with Parkinson disease","volume":"66","author":"Goetz","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2013.05.005_bib0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2006.05.014","article-title":"Rasagiline-associated motor improvement in pd occurs without worsening of cognitive and behavioral symptoms","volume":"248","author":"Elmer","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.phrs.2013.05.005_bib0175","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/mds.21048","article-title":"Effects of tyramine administration in Parkinson's disease patients treated with selective mao-b inhibitor rasagiline","volume":"21","author":"deMarcaida","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0180","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1468-1331.2011.03512.x","article-title":"Effect of rasagiline as adjunct therapy to levodopa on severity of off in Parkinson's disease","volume":"18","author":"Stocchi","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0185","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1468-1331.2011.03484.x","article-title":"Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease","volume":"19","author":"Tolosa","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the adagio study): prespecified and post-hoc analyses of the need for additional therapies, changes in updrs scores, and non-motor outcomes","volume":"10","author":"Rascol","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0195","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/mds.23519","article-title":"Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops","volume":"26","author":"Clarke","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0200","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.20914","article-title":"Minimal clinically important change on the unified Parkinson's disease rating scale","volume":"21","author":"Schrag","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson's disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0210","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0215","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson's disease in rats: an evaluation of 6-ohda lesions of the nigrostriatal pathway","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1016\/j.phrs.2013.05.005_bib0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2011.05.027","article-title":"Progress in defining the premotor phase of Parkinson's disease","volume":"310","author":"Tolosa","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.phrs.2013.05.005_bib0225","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/mds.23926","article-title":"Explaining adagio: a critical review of the biological basis for the clinical effects of rasagiline","volume":"26","author":"Jenner","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.phrs.2013.05.005_bib0230","first-page":"535","article-title":"Rasagiline: effectiveness and protection in Parkinson's disease","volume":"51","author":"Pagonabarraga","year":"2010","journal-title":"Rev Neurol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T15:22:52Z","timestamp":1539616972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661813000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":46,"alternative-id":["S1043661813000972"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2013.05.005","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2013.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}